Farm animals and aquaculture cryopreservation partnership announced
With the aim to jointly commercialise a global cryopreservation offering for farm animals and aquaculture, Vitrafy Life Sciences Limited has announced that it has entered a 12-month Strategic Commercial Agreement with IMV Technologies — a French-based multinational conglomerate with over 500 million animal inseminations annually.
In a statement about the agreement, Vitrafy said the partnership is designed to integrate its next-generation cryopreservation technology with IMV’s globally recognised offering. “This agreement with IMV Technologies represents a significant step in Vitrafy’s commercialisation strategy,” Managing Director and CEO Brent Owens said.
“By partnering with the global leader in animal reproduction, we accelerate the validation and adoption of our cryopreservation technology at scale,” Owens added. “This Agreement creates immediate revenue opportunities but also positions Vitrafy for long-term growth through global market access, while we continue to advance our human health strategy in North America.”
Oliver Kohlhaas, CEO of IMV Technologies, commented: “Vitrafy’s unique nitrogen-free cryopreservation technology has the potential to improve post-thaw cell viability. We are excited to collaborate with Vitrafy to offer even better solutions for our customers.”
Noxopharm says paper reveals science behind its immune system platform
Clinical-stage Australian biotech company Noxopharm Limited says a Nature Immunology...
Neurosensing/neurostimulation implants session to be held on Monday
On Monday, a session at UNSW Sydney will include people who are benefiting from bioelectronics...
argenx and Monash University partner against autoimmune diseases
To advance a pioneering molecule for autoimmune diseases, global immunology company argenx has...
